• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

    7/10/25 9:06:37 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA, maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights.

    By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging members upstream as they are being more proactive with their health. As a result, potential risks can be identified earlier, while also supporting a range of health goals, such as optimizing conception attempts or making sustainable lifestyle changes.     

    "The more women understand about their bodies, the more empowered they are to partner with their health providers and articulate their health status and goals. Whether you are focused on conceiving your first child or managing changing weight and sleep issues through menopause, understanding your personal data is powerful—physically and emotionally," said Janet Choi, MD, Progyny Chief Medical Officer. "Taking control with physiologic data from the Oura Ring further supports Progyny's focus on raising the bar and elevating health outcomes."

    With the ability to continuously track key health metrics, such as sleep patterns, cycle insights, cardiovascular health, stress levels, and more, ŌURA helps women understand their bodies so they can achieve optimal health. For those trying to conceive, these insights can help pinpoint fertile windows and support reproductive planning. During perimenopause or menopause, they can help identify patterns, guide impactful lifestyle adjustments, and inform meaningful conversations with providers. When needed, care plans, including personalized recommendations around sleep, nutrition, movement, and stress to support the body's changing needs can be developed.

    "Reproductive health management starts long before a doctor's visit—it begins with daily awareness of your body's patterns," said Dorothy Kilroy, Chief Commercial Officer at ŌURA. "By partnering with Progyny, we're bridging the gap between those daily health patterns and clinical care, helping people navigate fertility and family planning with greater clarity, confidence, and support. This collaboration brings Oura's powerful health signals into a setting where they can truly make a difference—guiding smarter care, earlier interventions, and more personalized journeys."

    Oura Ring and Oura Membership will be available to Progyny clients, including employers and health plans, beginning in early 2026.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For More Information, Please Contact:

    Media:

    Alexis Ford

    [email protected]

    Investors:

    James Hart

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PGNY
    SEC Filings

    See more
    • Progyny Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Progyny, Inc. (0001551306) (Filer)

      7/8/25 8:21:15 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 144 filed by Progyny Inc.

      144 - Progyny, Inc. (0001551306) (Subject)

      6/3/25 12:05:25 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/28/25 4:37:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

      NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA, maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging members upstream as they are being more proactive with their health. As a result, potential risks can be identified earlier, while also supporting a range of health goals, such as optimizing

      7/10/25 9:06:37 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report

      Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the "revolver" or the "facility") which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expe

      7/8/25 8:09:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health

      NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that it is adding pelvic floor therapy to its comprehensive offering of women's health and family building solutions. With the expansion of its network of specialty trained women's health providers, and the addition of digital therapy, the company is further deepening its commitment to increasing the accessibility of specialized, timely care across the spectrum from preconception and maternal health to midlife and menopause. One in three women experience pelvic floor issues, with one in five needing to undergo surgery to treat their pelv

      6/24/25 9:10:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Progyny from Market Perform to Outperform and set a new price target of $28.00

      7/8/25 11:08:47 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.84% to 222,312 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      7/2/25 4:10:43 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 7,977 shares, decreasing direct ownership by 1% to 547,541 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      7/2/25 4:09:09 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Director Scott Cheryl sold $59,037 worth of shares (2,675 units at $22.07), decreasing direct ownership by 16% to 14,112 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/12/25 5:07:13 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

      5/14/25 9:05:48 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      12/6/24 10:11:35 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      11/14/24 4:31:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      2/14/24 6:29:49 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Financials

    Live finance-specific insights

    See more
    • Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report

      Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the "revolver" or the "facility") which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expe

      7/8/25 8:09:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care